Strattec Security Corporation Q4 2026 Earnings Call Summary

Shattuck Labs (STTK) plans a Phase 2 trial for SL-325 in hidradenitis suppurativa, enrolling 150 patients. The trial will evaluate two doses against placebo, with primary endpoints at Week 16. Data is expected in 2028. The company also appointed Shoba Ravichandran as SVP, Clinical Development, and confirmed its cash runway extends into 2029.

Shattuck Labs (STTK) plans to start a Phase 2 trial in 2026 for SL-325 in hidradenitis suppurativa, with data expected in 2028. The company also appointed Shoba Ravichandran as Senior Vice President, Clinical Development. Cash runway is expected to last until 2029.

Strattec (STRT) reported fiscal 2026 net sales of $579.4M, up 2.5%, with Q4 sales at $151.8M. Gross margin expanded to 16.5%, and adjusted EPS was $2.06. The company faced a $10M EV program revenue headwind but offset it with pricing benefits. Cash increased to $108.2M, with no debt. For 2027, management expects a 2% production decline and plans $12M in capex. Share repurchases totaled $7.4M in Q4, with $40M authorized for future buybacks. Risks include softer industry production and foreign cur

Strattec Security (STRT) reported flat sales but expanded gross margin to 16.5% due to pricing and restructuring savings. Adjusted EPS increased to $6.88, and net income grew 10%. The company reduced headcount by 21%, automated workstations, and upgraded technology systems. Strattec plans further transformation, share repurchases, and potential acquisitions, with cash deployment priorities including organic growth and debt repayment.

Strattec Security Corp (STRT) reported Q4 2026 earnings with record revenue but expects softer industry production in fiscal 2027, with North American production down ~2% and a ~6% decline at its three largest customers. Foreign exchange headwinds, particularly the Mexican peso, could pressure gross margins by ~100 basis points. Q4 gross margin declined to 15.6% from 16.7% in the prior year. The company aims to offset headwinds through pricing and continuous improvement actions, maintaining a lo

Strattec Security reported Q4 gross profit of $23.6M, down from $25.4M YoY, with net income at $3.9M ($0.95 per share) vs. $8.3M ($2.01 per share) prior year. Adjusted net income was $8.4M ($2.06 per share), unchanged YoY. Full-year sales rose 2.5% to $565.1M, with adjusted EBITDA up 15% to $50.5M. The company authorized a $40M share repurchase program and expects fiscal 2027 challenges, including a 2% NA production decline and FX headwinds.